Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

255
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
255
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Freezing of Gait Levodopa Response Pattern in Parkinson's Disease Provides Clues to Pathophysiology.

The European journal of neuroscience·2026
Same author

Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

Annals of neurology·2026
Same author

Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

Neurology·2026
Same author

Brain regional susceptibility to tauopathy in individuals at risk for chronic traumatic encephalopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Dose-dependent white matter changes associated with repetitive head impacts in former American football players.

Brain communications·2026
Same author

Cognitive, biomarker, and neuroimaging indices associated with traumatic encephalopathy syndrome across two independent athlete cohorts.

Alzheimer's research & therapy·2026

Related Experiment Video

Updated: Sep 9, 2025

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K

Apolipoprotein E, Executive Function, and Falls across Cognitive Status: A Cross-Sectional Study.

Ferdinand Delgado1,2, Fang Yu3, Daniel S Peterson4

  • 1College of Health and Human Services, Department of Kinesiology, University of New Hampshire, Durham, New Hampshire, USA, ferdinanddelgadophd@gmail.com.

Dementia and Geriatric Cognitive Disorders
|August 28, 2025
PubMed
Summary
This summary is machine-generated.

Apolipoprotein E4 (ApoE4) does not affect how executive function (EF) relates to falls. However, EF impacts falls differently across cognitive statuses in older adults.

Keywords:
AgingAlzheimer’s diseaseExecutive functionFalls

More Related Videos

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.1K
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

13.8K

Related Experiment Videos

Last Updated: Sep 9, 2025

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.9K
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.1K
Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

13.8K

Area of Science:

  • Neuroscience
  • Gerontology
  • Public Health

Background:

  • Falls are a major public health concern in older adults.
  • Executive function (EF) impairment is a known risk factor for falls.
  • The role of Apolipoprotein E4 (ApoE4) in the EF-falls relationship is not well understood.

Purpose of the Study:

  • To investigate the moderating effect of ApoE4 on the relationship between EF and falls.
  • To examine this relationship across different cognitive statuses: unimpaired cognition, mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia.

Main Methods:

  • Cross-sectional analysis of 486 participants from the Arizona Study of% Aging and Neurodegenerative Disorders.
  • EF assessed via a composite latent variable (Trail Making Test, Stroop Interference, Digit Span, Clock Drawing, verbal fluency).
  • ApoE genotypes determined; logistic regression used to analyze fall history and future falls.

Main Results:

  • ApoE4 did not significantly moderate the EF-falls relationship.
  • EF was associated with fall history in individuals with unimpaired cognition and MCI, but not AD dementia.
  • Covariates like Parkinson's scale elements, medical conditions, and depression were associated with fall history; medical conditions and fall history with future falls.

Conclusions:

  • ApoE4 does not alter the association between EF and falls.
  • The influence of EF on falls is dependent on an individual's cognitive status.